In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualized neoantigen therapy plus pembrolizumab for resected stage IIB to IV melanoma. No data were shared, only descriptive findings of "statistically signficant" and "clinically meaningful" results. As James puts it, one of these is binary, the other is subjective.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Melanoma Matters Pod. Innehållet i podden är skapat av Melanoma Matters Pod och inte av, eller tillsammans med, Poddtoppen.